目的 探討阿卡波糖聯(lián)合諾和銳30治療2型糖尿病血糖控制欠佳者的臨床療效。方法 南京大學(xué)醫(yī)院收治的52例血糖控制欠佳的2型糖尿病患者隨機分為治療組（27例）和對照組（25例）。對照組給予諾和銳30注射液，2次/d，早晚餐前皮下注射。治療組于三餐前口服阿卡波糖片，50 mg/次，3次/d，諾和銳30注射液的用法同對照組。治療12周后，比較兩組患者治療前后空腹血糖（FBG）、餐后2 h血糖（2 h PG）、糖化血紅蛋白（HbA1c）、體質(zhì)量指數(shù)（BMI）、血脂變化情況及胰島素用量。結(jié)果 治療后，兩組患者FBG、HbA1c均較治療前明顯降低，治療前后差異有統(tǒng)計學(xué)意義（P<0.05）。治療后，治療組患者HbA1c水平明顯低于對照組，兩組比較差異有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組全天七點血糖水平均較治療前明顯降低，同組治療前后差異有統(tǒng)計學(xué)意義（P<0.05）；同時，治療組三餐后2 h PG均顯著低于對照組，兩組比較差異有統(tǒng)計學(xué)意義（P<0.05）。治療組血糖達(dá)標(biāo)時間明顯短于對照組，兩組比較差異有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 阿卡波糖聯(lián)合諾和銳30治療血糖控制欠佳的2型糖尿病患者具有較好的臨床療效，可有效控制餐后血糖水平，具有良好的臨床應(yīng)用價值。

Objective To investigate the clinical effect of acarbose combined with Novomix 30 in the treatment of type 2 diabetes of patients who had a suboptimal response to therapy. Methods Fifty-two cases of type 2 diabetes in Hospital of Nanjing University, who had a suboptimal response to therapy, were randomly divided into treatment group (27 cases) and control group (25 cases). Patients in the control group were sc administered with Novomix 30 Injection before breakfast and dinner, twice daily; Patients in the treatment group were po administered with Acarbose Tablets, 50 mg/time, three times daily, while the usage of Novomix 30 Injection were the same as the control group. After 12 weeks of the continuous therapy, fasting blood glucose (FBG), 2 h post meal blood glucose (2 h PG), glycosylated hemoglobin A1c (HbA1c), body mass index (BMI), blood lipid, and the dosage of insulin in the two groups were compared. Results After the treatment, FBG and HbA1c of the two groups were significantly lower than those before the treatment, and the differences were statistically significant in the same group before and after the treatment (P < 0.05). After the treatment, the level of HbA1c in the treatment group was lower than that in the control group, with the significant difference between the two groups (P < 0.05). After the treatment, the blood sugar level of seven observation point throughout the day in the two groups were significantly decreased, and the differences were statistically significant in the same group before and after the treatment (P < 0.05). At the same time, 2 h PG after three meals of the treatment group was lower than that in the control group, with the significant difference between the two groups (P < 0.05). Blood sugar up to the standard time of the treatment group was obviously shorter than that in the control group, with the significant difference between the two groups (P < 0.05). Conclusion Acarbose combined Novomix 30 has a good clinical efficacy in the treatment of type 2 diabetes of patients who have a suboptimal response to therapy, and can effectively control the postprandial blood glucose, which has good clinical application value.